Plus Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new institutional investors and Company insiders to issue up to an aggregate of 3,238,627 shares of its common stock at an issue price of $2.022 per share for the gross proceeds of $6,548,503.794; Series A warrants to purchase up to an aggregate of 3,238,627 shares of common stock at an exercise price of $1.772 per share for an aggregate gross proceeds of up to $5,738,847.044 and Series B warrants to purchase up to 3,238,627 shares of common stock at an exercise price of $1.772 per share for an aggregate of up to approximately $5,738,847.044 for the aggregate gross proceeds of $17,948,503.794 on May 5, 2024. The Series B warrants will be exercisable until the one-year anniversary of the effectiveness of a registration statement covering the resale of shares of common stock underlying the Series B warrants. The private placement is expected to close on or about May 8, 2024, subject to satisfaction of customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -10.37% | -23.83% | -16.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.00% | 8.39M | |
+23.13% | 46.93B | |
+37.35% | 39.08B | |
-8.73% | 38.48B | |
+28.09% | 31.01B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+45.05% | 14.15B | |
+32.23% | 12.53B | |
-6.56% | 11.36B |
- Stock Market
- Equities
- PSTV Stock
- News Plus Therapeutics, Inc.
- Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC